List of Excipients in Branded Drug DESVENLAFAXINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alembic Pharmaceuticals Limited	DESVENLAFAXINE	desvenlafaxine	46708-152	ALGINIC ACID
Alembic Pharmaceuticals Limited	DESVENLAFAXINE	desvenlafaxine	46708-152	CELLULOSE, MICROCRYSTALLINE
Alembic Pharmaceuticals Limited	DESVENLAFAXINE	desvenlafaxine	46708-152	CITRIC ACID MONOHYDRATE
Alembic Pharmaceuticals Limited	DESVENLAFAXINE	desvenlafaxine	46708-152	FERRIC OXIDE RED
Alembic Pharmaceuticals Limited	DESVENLAFAXINE	desvenlafaxine	46708-152	HYPROMELLOSE
Alembic Pharmaceuticals Limited	DESVENLAFAXINE	desvenlafaxine	46708-152	MAGNESIUM STEARATE
Alembic Pharmaceuticals Limited	DESVENLAFAXINE	desvenlafaxine	46708-152	POLYETHYLENE GLYCOL 6000

Generic Drugs Containing DESVENLAFAXINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	desvenlafaxine	0054-0603	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	desvenlafaxine	0054-0603	FD&C BLUE NO. 1
Hikma Pharmaceuticals USA Inc	desvenlafaxine	0054-0603	FD&C RED NO. 40
Hikma Pharmaceuticals USA Inc	desvenlafaxine	0054-0603	FD&C YELLOW NO. 6
Hikma Pharmaceuticals USA Inc	desvenlafaxine	0054-0603	HYPROMELLOSE 2208
Hikma Pharmaceuticals USA Inc	desvenlafaxine	0054-0603	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	desvenlafaxine	0054-0603	POLYETHYLENE GLYCOL 1000

What are the Most Frequently-Used Excipients in DESVENLAFAXINE?

# Of NDCs	Excipient
2	AMMONIA
44	CELLULOSE, MICROCRYSTALLINE
1	CI 77891
2	D&C RED NO. 27 ALUMINUM LAKE
2	ETHYLCELLULOSE
2	FD&C BLUE NO. 1
2	FD&C BLUE NO. 2

Desvenlafaxine Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Desvenlafaxine is a mature, genericized antidepressant market in which excipient differentiation is more commercially realistic than new-chemical-entity patent protection. The strongest opportunities are extended-release matrix optimization, tablet-size reduction, abuse-deterrence positioning, improved manufacturing robustness, and differentiated presentations such as sprinkle or orally disintegrating products. The core technical constraint is controlled delivery of a highly water-soluble serotonin-norepinephrine reuptake inhibitor from a low-dose, once-daily tablet.

What is the commercial status of desvenlafaxine?

Desvenlafaxine is the active metabolite of venlafaxine and is marketed primarily as desvenlafaxine succinate extended-release tablets. Pfizer commercialized the product under the brand name Pristiq for major depressive disorder. The standard strengths are 25 mg, 50 mg, and 100 mg, with 50 mg generally used as the recommended therapeutic dose. The product is administered once daily and should be swallowed whole rather than crushed, chewed, or dissolved.[1]

Attribute	Desvenlafaxine commercial profile
Active ingredient	Desvenlafaxine succinate monohydrate
Pharmacological class	Serotonin-norepinephrine reuptake inhibitor
Primary indication	Major depressive disorder
Main dosage form	Once-daily extended-release tablet
Key strengths	25 mg, 50 mg, 100 mg
Reference product	Pristiq
Original sponsor	Wyeth, later Pfizer
Generic pathway	Abbreviated New Drug Application
Primary formulation issue	Sustained release of a water-soluble drug
Principal commercial risk	Price erosion from multiple generic suppliers

The market is no longer dependent on a single branded product. Generic desvenlafaxine extended-release tablets have entered the U.S. market, reducing the value of ordinary composition-of-matter and basic tablet patents. Commercial value has shifted toward cost-efficient manufacturing, supply reliability, differentiated dosage forms, and formulation-specific intellectual property.

What excipients are used in desvenlafaxine extended-release tablets?

The reference product uses conventional pharmaceutical excipients for matrix formation, compression, lubrication, and film coating. Exact excipient systems vary among manufacturers and strengths.

Typical functional categories include:

Excipient category	Representative materials	Function
Hydrophilic matrix former	Hypromellose	Controls water penetration and drug diffusion
Diluent	Microcrystalline cellulose	Provides tablet bulk and compressibility
Binder	Povidone or related polymer	Improves granule and tablet strength
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces ejection force and tooling adhesion
Anti-adherent	Talc	Supports processing and coating performance
Film former	Polyvinyl alcohol or hypromellose	Protects and identifies the tablet
Plasticizer	Polyethylene glycol or similar material	Improves coating flexibility
Opacifier or colorant	Titanium dioxide and iron oxides, where applicable	Product identification and light protection

The reference formulation demonstrates that desvenlafaxine does not require an exotic excipient platform. Its formulation challenge arises from the release profile. Desvenlafaxine succinate has high aqueous solubility, which can produce rapid dissolution unless the matrix, coating, tablet geometry, and process conditions are tightly controlled.

How does excipient selection control desvenlafaxine release?

The most important formulation lever is the hydrophilic polymer system. Hypromellose hydrates after contact with gastrointestinal fluid, creating a gel layer that limits solvent penetration and drug diffusion. Polymer viscosity grade, substitution pattern, particle size, concentration, and distribution within the tablet can materially change dissolution.

A development program should evaluate:

1. Polymer viscosity and concentration.
2. Drug-to-polymer ratio.
3. Direct compression versus wet granulation.
4. Granule porosity and particle-size distribution.
5. Tablet hardness and friability.
6. Compression force and dwell time.
7. Tablet dimensions and surface-area-to-volume ratio.
8. Lubrication level and blending time.
9. Dissolution behavior across acidic and neutral media.
10. Alcohol-induced release changes.

For a highly soluble drug, increasing polymer concentration alone may not produce a robust product. Excessive polymer can reduce manufacturability, increase tablet size, and create slow or variable release. A lower polymer level may improve tablet economics but increase the risk of an early release spike.

Hydrophilic matrix strategy

A conventional hypromellose matrix is commercially attractive because it is widely accepted by regulators, available from multiple suppliers, and compatible with standard high-speed tablet equipment. The main opportunity is not simply substituting one grade of hypromellose for another. The stronger strategy is to engineer the entire matrix around reproducible gel formation and low sensitivity to manufacturing variation.

Potential improvements include:

• Combining high- and low-viscosity hypromellose grades.
• Using a polymer blend with a complementary diffusion and erosion profile.
• Incorporating polyethylene oxide or carbomer where justified by compatibility and processing data.
• Modifying granule porosity to reduce burst release.
• Using functional coating layers to supplement the matrix.
• Reducing tablet weight while preserving dissolution performance.

Polyethylene oxide can provide strong gel formation but may create processing and regulatory complexity. Carbomers can improve retardation but are sensitive to ionic strength and pH. These systems may support differentiated patents, but they require more extensive formulation and stability work than conventional hypromellose.

What formulation patents can protect desvenlafaxine products?

Excipient patents for desvenlafaxine should protect a defined technical relationship rather than a generic list of ingredients. Broad claims covering "desvenlafaxine plus hypromellose" are vulnerable because hydrophilic matrix systems are well established.

More defensible claim themes include:

• A specified desvenlafaxine-to-polymer ratio that produces a defined dissolution profile.
• A multilayer tablet with separate immediate-release and extended-release regions.
• A controlled-release tablet with a specified polymer blend and tablet hardness.
• A formulation that limits alcohol-induced dose dumping.
• A low-weight tablet with equivalent pharmacokinetics and dissolution.
• A formulation with improved stability under high humidity.
• A manufacturing process that produces narrow dissolution variability.
• A novel coating system that controls initial wetting or gastrointestinal release.
• A sprinkle or multiparticulate formulation that preserves extended release after administration with soft food.
• A pediatric or geriatric dosage form with acceptable taste and controlled delivery.

Patent value increases when the claims connect composition, process, and measurable performance. Dissolution data should cover multiple batches, multiple strengths, pH conditions, agitation rates, and alcohol challenge conditions. Pharmacokinetic data can strengthen claims where formulation changes produce a meaningful exposure profile.

When does desvenlafaxine lose exclusivity?

Desvenlafaxine's principal U.S. exclusivity period has ended, and generic extended-release products are commercially available. The original Pristiq patent estate included patents directed to desvenlafaxine and pharmaceutical compositions. Historical patent records identify U.S. Patent No. 6,673,838 as a key patent associated with desvenlafaxine technology.[2]

Exclusivity category	Commercial position
New chemical entity exclusivity	Expired
Original branded formulation exclusivity	Expired or no longer sufficient to block routine generic entry
Generic competition	Established
Current opportunity	Formulation, delivery, manufacturing, and market-specific differentiation
Biosimilar pathway	Not applicable

Patent expiry does not eliminate all IP risk. A company can still pursue formulation patents, process patents, device claims, or method-of-use claims. Those rights must be evaluated against the approved product, generic labels, FDA Orange Book listings, prosecution history, and prior-art disclosures.

What is the Orange Book status of desvenlafaxine?

Desvenlafaxine is regulated as a small-molecule drug. It is therefore subject to the ANDA pathway and Orange Book patent-certification framework rather than the biosimilar pathway.

Relevant regulatory points include:

• Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.
• A Paragraph IV certification can challenge an unexpired patent listed in the Orange Book.
• A Paragraph IV notice can trigger patent litigation and a potential 30-month stay of ANDA approval under the Hatch-Waxman framework.
• A new formulation with a distinct dosage form or delivery mechanism may require a new drug application or a suitability determination, depending on the product design.
• New excipients or materially different excipient levels may attract additional FDA scrutiny, especially where they affect absorption, release, tolerability, or bioequivalence.[3]

The main regulatory barrier for a new desvenlafaxine extended-release tablet is usually not clinical efficacy. It is demonstrating equivalent exposure and equivalent release behavior without relying on the branded manufacturer's formulation details.

How strong is the patent estate for desvenlafaxine excipient products?

The patent estate for a conventional generic desvenlafaxine tablet is weak because the active ingredient, once-daily administration, and common hydrophilic matrix approaches are mature technologies. A narrowly tailored formulation patent can still have value, but its strength depends on four factors:

Factor	Strong position	Weak position
Claim scope	Defined composition and performance limits	Open-ended ingredient list
Technical effect	Reduced dose dumping, improved stability, or lower variability	Routine release control
Prior art	Limited disclosure of the claimed combination	Extensive disclosure of similar matrices
Commercial relevance	Covers the marketed dosage form or a needed manufacturing step	Covers an impractical or noncommercial embodiment

A formulation patent is more valuable if it blocks a low-cost route to approval. A patent that protects a minor coating color or nonessential excipient substitution is unlikely to create meaningful market power.

What commercial opportunities exist for desvenlafaxine excipients?

Low-cost generic extended-release tablets

The largest opportunity remains manufacturing efficiency. Excipient suppliers can target:

• Direct-compression matrix systems.
• High-throughput granulation platforms.
• Lower tablet weight.
• Reduced magnesium stearate sensitivity.
• Improved content uniformity at low drug loading.
• More consistent dissolution across tablet strengths.
• Robust processing at multiple contract manufacturing sites.

A platform excipient that reduces granulation steps or permits direct compression may create value even without product-specific exclusivity. The commercial proposition is lower conversion cost, fewer deviations, and easier technology transfer.

Sprinkle or multiparticulate formulations

A sprinkle product could address patients who have difficulty swallowing tablets. The technical requirements are demanding. Multiparticulates must maintain extended release after dispersion, avoid dose dumping when chewed, and remain acceptable when mixed with soft food.

Potential systems include:

• Coated drug-loaded pellets.
• Matrix mini-tablets.
• Multiparticulate capsules.
• Taste-masked coated particles.
• Sachets containing controlled-release granules.

This opportunity would likely require a new regulatory strategy and may support formulation and use patents. It also carries higher development risk than a conventional tablet because food, chewing, particle-size distribution, and dose uniformity become central issues.

Orally disintegrating or orally dispersible products

An orally disintegrating product could improve administration for patients with swallowing difficulty. The formulation must balance rapid oral disintegration with delayed gastrointestinal drug release. A practical design may use protected extended-release particles embedded in a rapidly disintegrating tablet.

Key technical risks include:

• Premature release from damaged particles.
• Bitter taste from exposed desvenlafaxine.
• Moisture sensitivity.
• Friability during packaging and transport.
• Food and beverage compatibility.
• Bioequivalence relative to the reference tablet.

This product would be commercially differentiated but would face competition from low-cost standard generics.

Abuse-deterrent and alcohol-resistant systems

Desvenlafaxine is not generally positioned as a high-priority opioid-style abuse-deterrence product. The commercial rationale for an abuse-deterrent system is therefore limited. A more relevant opportunity is resistance to alcohol-induced release acceleration.

An alcohol-resistant matrix could support a formulation patent if it demonstrates a meaningful reduction in release change across clinically relevant alcohol concentrations. The evidence should include comparative dissolution under multiple media, alcohol levels, agitation conditions, and mechanical stress. Without a clear clinical or regulatory benefit, the additional excipient cost may not be commercially justified.

Pediatric and geriatric presentations

Major depressive disorder treatment includes patients who may have difficulty swallowing or require dose flexibility. Potential presentations include:

• Small-strength tablets.
• Oral granules.
• Sprinkle capsules.
• Taste-masked liquid-compatible particles.
• Lower-dose titration products.

The commercial opportunity depends on label support, prescribing practice, reimbursement, and the ability to demonstrate bioequivalence or clinically acceptable exposure. A liquid formulation is technically difficult because desvenlafaxine's release-control mechanism must remain stable in an aqueous vehicle.

What manufacturing and intellectual-property barriers affect entry?

The key manufacturing barriers are process reproducibility and dissolution control. A formulation may pass laboratory development but fail during commercial scale-up because granule density, polymer distribution, tablet porosity, and coating uniformity change with equipment size.

Important scale-up controls include:

• High-shear granulation endpoint.
• Binder addition rate.
• Drying loss-on-drying range.
• Granule particle-size distribution.
• Lubrication time.
• Compression force.
• Tablet tensile strength.
• Coating weight gain.
• Dissolution at multiple time points.

Potential IP barriers include:

• Active-ingredient composition patents in selected jurisdictions.
• Extended-release formulation patents.
• Manufacturing-process patents.
• Product-by-process claims.
• Method-of-treatment claims.
• Patents covering specific particle or multiparticulate architectures.
• Trade secrets involving granulation endpoints and scale-up parameters.

Geographic freedom to operate must be assessed separately. U.S. patent expiry does not establish freedom to commercialize in Europe, Canada, Japan, China, India, or Latin America. Patent term adjustments, supplementary protection certificates, divisional applications, and local prosecution outcomes can produce different expiry dates.

Which companies are challenging or competing with Pristiq?

The competitive field includes generic manufacturers supplying desvenlafaxine succinate extended-release tablets, as well as branded and generic alternatives in the broader SNRI market.

Competitive group	Product or strategy	Commercial implication
Generic desvenlafaxine manufacturers	Extended-release tablets	Price competition and supply concentration
Pfizer	Pristiq	Brand retention, residual prescriber recognition
Venlafaxine manufacturers	Immediate- and extended-release products	Therapeutic substitution
Duloxetine manufacturers	Delayed-release capsules	Alternative SNRI with different formulation profile
Specialty generics companies	Differentiated dosage forms	Potential niche pricing and product lifecycle extension
Excipient suppliers	Matrix and coating platforms	Enabling technology rather than finished-dose competition

Desvenlafaxine competes clinically with venlafaxine, duloxetine, and other antidepressants. Its commercial differentiation is limited unless a supplier or manufacturer offers a meaningful advantage in adherence, swallowing, tolerability, dosing flexibility, or supply reliability.

What generic launch scenarios exist for desvenlafaxine?

Standard tablet commoditization

This is the base case. Multiple suppliers compete primarily on price, manufacturing scale, wholesaler access, and supply continuity. Excipient differentiation has limited pricing power unless it reduces cost or prevents manufacturing failures.

Formulation-led premium generic

A multiparticulate, sprinkle, or orally disintegrating product could support higher pricing. The product would need a clear patient or prescriber benefit and a regulatory pathway that does not require a full clinical development program.

Supply-constrained opportunity

Temporary shortages or limited supplier participation can create an opportunity for a reliable manufacturer with validated excipient sourcing. Dual-source polymer qualification and resilient coating-material supply can be commercially important even when the underlying formulation is unprotected.

Licensed technology platform

An excipient company could license a validated extended-release platform to multiple generic manufacturers. The strongest licensing model would combine formulation know-how, process parameters, analytical methods, and regulatory support. A simple sale of commodity hypromellose is less defensible.

What licensing deals are relevant to desvenlafaxine excipient strategy?

The most commercially plausible licensing structures are:

1. Nonexclusive excipient-platform licenses to generic manufacturers.
2. Territory-specific licenses for differentiated dosage forms.
3. Co-development agreements for sprinkle or orally disintegrating products.
4. Supply-plus-license agreements tied to minimum annual volumes.
5. Technology-transfer agreements covering formulation and scale-up.
6. Royalty-bearing licenses for patents that claim alcohol-resistant or low-variability release.

The licensor should avoid relying solely on a composition patent. A stronger package combines patent rights with reference dissolution data, manufacturing controls, analytical methods, stability data, and regulatory documentation.

What is the revenue exposure of Pristiq and desvenlafaxine generics?

The commercial market is exposed to rapid price erosion because desvenlafaxine is a mature small-molecule product with multiple generic substitutes. Brand revenue is vulnerable to formulary substitution, while generic revenue depends on volume, supply reliability, and cost position.

For an excipient supplier, the addressable value is usually a fraction of finished-product revenue. The most attractive targets are formulations with:

• Large annual tablet volumes.
• Multiple strengths using one platform.
• High failure cost from dissolution variability.
• Limited qualified excipient suppliers.
• A realistic path to ANDA approval.
• A defensible formulation or process patent.

A commodity excipient substitution rarely supports a substantial premium. A platform that reduces batch failure, shortens processing time, or enables a differentiated dosage form has greater commercial value.

How should companies prioritize desvenlafaxine excipient investments?

A practical development ranking is:

Opportunity	Technical difficulty	IP potential	Commercial attractiveness
Conventional hypromellose matrix optimization	Low to moderate	Low to moderate	Moderate
Lower-weight direct-compression tablet	Moderate	Moderate	Moderate to high
Alcohol-resistant matrix	Moderate	Moderate to high	Moderate
Sprinkle multiparticulates	High	High	Moderate to high
Orally disintegrating extended-release tablet	High	High	Moderate
Liquid extended-release formulation	Very high	High	Uncertain
Commodity excipient substitution	Low	Low	Low

The best near-term strategy is a robust, low-cost matrix platform that improves dissolution consistency and manufacturing throughput. The best longer-term strategy is a differentiated multiparticulate or orally dispersible product supported by formulation patents and a clear patient-use rationale.

Key Takeaways

• Desvenlafaxine is a mature genericized SNRI market centered on once-daily extended-release tablets.
• The principal formulation challenge is controlling release from a highly water-soluble drug.
• Hypromellose, microcrystalline cellulose, povidone, colloidal silicon dioxide, magnesium stearate, talc, and conventional coating materials provide a standard excipient foundation.
• Broad excipient claims are vulnerable to prior art. Stronger patents require defined compositions linked to dissolution, alcohol resistance, stability, manufacturability, or dosage-form performance.
• The most credible commercial opportunities are low-cost matrix optimization, lower-weight tablets, sprinkle products, orally disintegrating extended-release systems, and manufacturing platforms.
• Biosimilar risk is not applicable because desvenlafaxine is a small-molecule drug.
• Paragraph IV litigation risk is materially lower for the original product than during the first generic-entry period, but new formulation patents can create fresh Hatch-Waxman disputes.
• Licensing value is highest when excipient supply is combined with formulation know-how, scale-up controls, analytical methods, and regulatory support.

FAQs

Can desvenlafaxine be formulated as an immediate-release tablet?

Yes, but an immediate-release product would change the pharmacokinetic profile and may require a different regulatory and clinical justification. The commercial reference product is extended release, so an immediate-release formulation would not be a routine generic substitute.

Which polymer is most suitable for desvenlafaxine extended release?

Hypromellose is the most practical starting point because it is well established, broadly supplied, and compatible with hydrophilic matrix tablets. Polymer grade, concentration, particle size, and processing conditions determine performance.

Can desvenlafaxine tablets be made smaller?

Potentially. Smaller tablets may be achieved through higher drug loading, optimized granulation, direct compression, or more efficient polymer systems. The design must preserve content uniformity, mechanical strength, dissolution, and bioequivalence.

Is a desvenlafaxine liquid formulation commercially attractive?

It is technically possible but challenging. Maintaining extended release in an aqueous vehicle, controlling taste, preserving stability, and demonstrating equivalent exposure would create a substantially higher development burden than a tablet or multiparticulate product.

Can an excipient supplier obtain patent protection without discovering a new desvenlafaxine molecule?

Yes. Protection may be available for a novel formulation, dosage form, manufacturing process, release profile, or excipient combination that produces a non-obvious technical effect. Patent strength depends on claim construction, comparative data, and the prior-art record.

References

1. Pfizer Inc. (2023). Pristiq (desvenlafaxine) extended-release tablets prescribing information. U.S. Food and Drug Administration.

2. United States Patent and Trademark Office. (2004). U.S. Patent No. 6,673,838: Desvenlafaxine succinate and pharmaceutical compositions. U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (2017). Guidance for industry: ANDAs for certain highly soluble, highly permeable, and highly variable drug products. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. U.S. Department of Health and Human Services.